Skip to main content
Onco-Innovations logo

Onco-Innovations — Investor Relations & Filings

Ticker · ONCO ISIN · CA68237C1059 NEO Professional, scientific and technical activities
Open in API
Filings indexed 86 across all filing types
Latest filing 2026-01-15 Audit Report / Informat…
Country CA Canada
Listing NEO ONCO

About Onco-Innovations

https://oncoinnovations.com/

Onco-Innovations is a biotechnology company specializing in oncology research and the development of cutting-edge therapies to prevent and treat cancer. The company focuses on next-generation treatments, particularly those targeting solid tumors, leveraging an exclusive global license for patented technology. To advance precision oncology, Onco-Innovations utilizes the SynoGraph™ AI platform (acquired through Inka Health) to accelerate patient identification, optimize treatment planning, and streamline its drug development pipeline.

Recent filings

Filing Released Lang Actions
Letter from successor auditor.pdf
Audit Report / Information Classification · 1% confidence The document is a formal letter from an accounting firm (MNP LLP) to various Canadian Securities Commissions regarding a 'Notice of Change of Auditor'. This is a regulatory requirement under National Instrument 51-102. Since it is a specific regulatory filing regarding auditor changes and does not fit into the other specific categories like financial reports or shareholder communications, it is best classified as a general regulatory filing. FY 2026
2026-01-15 English
Cover letter.pdf
Audit Report / Information Classification · 1% confidence The document is a formal notice to securities commissions regarding a change of auditor, including required letters from the former and successor auditors. It does not fit into the specific categories for financial reports, earnings, or governance reports. As it is a regulatory filing required by National Instrument 51-102 that does not fall into the other specific categories provided, it is best classified as a general regulatory filing. FY 2026
2026-01-15 English
Notice.pdf
Audit Report / Information Classification · 1% confidence The document is a formal 'Notice of Change of Auditor' filed by Onco-Innovations Limited pursuant to National Instrument 51-102. It details the resignation of the predecessor auditor and the appointment of a successor auditor, including confirmation of no reportable events. Since this is a specific regulatory notification regarding corporate governance and auditor status that does not fit into the other categories like 'Board/Management Information' (which focuses on personnel changes) or 'Audit Report' (which is the audit itself), it is best classified as a Regulatory Filing. FY 2025
2026-01-15 English
Decision Document / Order for Application - French.pdf
Regulatory Filings Classification · 1% confidence The document is a formal decision (DÉCISION N° : 2026-FS-1001846) issued by the Autorité des marchés financiers (AMF) regarding a request for an exemption (dispense) from regulatory requirements for Onco-Innovations Limited. It pertains to legal/regulatory compliance regarding prospectus filing obligations. Since it is a specific regulatory order/ruling that does not fit into standard financial reporting categories like 10-K or ER, it falls under the 'Regulatory Filings' category.
2026-01-07 French
NI 44-101 Notice of intent to qualify – English.pdf
Regulatory Filings Classification · 1% confidence The document is a formal notice filed with various Canadian securities commissions regarding the issuer's intention to qualify for short form prospectus distributions under National Instrument 44-101. It does not contain financial results, dividend declarations, or specific transaction details, but rather serves as a regulatory notification of intent. As it does not fit into specific categories like M&A, share issuance, or financial reporting, it falls under the general regulatory filing category.
2025-12-19 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109F2', which is a standard Canadian regulatory filing for the 'Certification of Interim Filings'. It is signed by the CEO and confirms the accuracy and internal controls related to the interim financial report and MD&A. Since this is a regulatory certification document rather than the financial report itself, and it does not fit into the specific categories like 10-K, IR, or MANG, it is best classified as a Regulatory Filing (RNS).
2025-12-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.